These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. The advent of biosimilars for the treatment of diabetes: current status and future directions. Polimeni G; Trifirò G; Ingrasciotta Y; Caputi AP Acta Diabetol; 2015 Jun; 52(3):423-31. PubMed ID: 25990669 [TBL] [Abstract][Full Text] [Related]
14. Biosimilars: how similar or dissimilar are they? Roger SD Nephrology (Carlton); 2006 Aug; 11(4):341-6. PubMed ID: 16889575 [TBL] [Abstract][Full Text] [Related]
15. Biosimilars in oncology: from development to clinical practice. Rak Tkaczuk KH; Jacobs IA Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633 [TBL] [Abstract][Full Text] [Related]
16. WHO informal consultation on regulatory evaluation of therapeutic biological medicinal products held at WHO Headquarters, Geneva, 19-20 April 2007. Joung J; Robertson JS; Griffiths E; Knezevic I; Biologicals; 2008 Jul; 36(4):269-76. PubMed ID: 18218324 [TBL] [Abstract][Full Text] [Related]
17. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States. Ahmed I; Kaspar B; Sharma U Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050 [TBL] [Abstract][Full Text] [Related]
18. Biosimilars: pharmacovigilance and risk management. Zuñiga L; Calvo B Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):661-9. PubMed ID: 20583204 [TBL] [Abstract][Full Text] [Related]
19. Biosimilars: Concepts and controversies. Gámez-Belmonte R; Hernández-Chirlaque C; Arredondo-Amador M; Aranda CJ; González R; Martínez-Augustin O; Sánchez de Medina F Pharmacol Res; 2018 Jul; 133():251-264. PubMed ID: 29428205 [TBL] [Abstract][Full Text] [Related]
20. Bioanalytical challenges of biosimilars. Islam R Bioanalysis; 2014 Feb; 6(3):349-56. PubMed ID: 24471955 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]